Issue Date: May 7, 2012
Novo Nordisk Will Add Jobs In U.S.
Danish drug firm Novo Nordisk plans to increase its U.S. workforce, now 4,100, by 15% in 2012. Sales positions will represent much of the growth in headcount, but the company says it is also recruiting scientists for its new type 1 diabetes R&D site in Seattle and workers for its manufacturing facility in Clayton, N.C. In separate news, Novo Nordisk has licensed heparosan-based drug delivery technology from Oklahoma City-based Caisson Biotech. The deal could be worth more than $100 million in milestone payments, Caisson says, if drugs using its technology reach the market.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society